Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); EU Approval Application In: tali EMEA OK Possible By Early 2012
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' rating on Protalix BioTherapeutics (NYSE: PLX) and $10 price target.
Canaccord analyst says, "We think ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We think ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
